Lexaria Bioscience (LEXX) Stock Price, News & Analysis

Company Overview

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a biotechnology company developing drug-delivery technologies designed to improve the way active pharmaceutical and nutritional compounds are absorbed and used by the body. Its principal technology, DehydraTECH, is intended to enhance the delivery, bioavailability, and performance of orally administered compounds.

The company has investigated DehydraTECH applications involving cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, antiviral compounds, and other active ingredients. Lexaria’s work includes formulation development, laboratory research, and human and animal studies aimed at evaluating the technology’s potential across pharmaceutical, wellness, and consumer products.

Lexaria is based in Kelowna, British Columbia, Canada, and conducts research and business activities through its corporate operations and commercial relationships. The company has historically focused on developing and protecting its intellectual property, with the potential to license or commercialize DehydraTECH-enabled products. Chris Bunka has served as the company’s chief executive officer and chairman.

Key Stats

• Today's Range: $3.12 to $3.90
• 50-Day Range: $2.77 to $14.15
• 52-Week Range: $2.77 to $21.60
• Volume: 198,409 shs
• Average Volume: 80,383 shs
• Market Capitalization: $7.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.50
• Consensus Rating: Hold

Lexaria Bioscience Stock Analysis - MarketRank™

Lexaria Bioscience scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Lexaria Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Lexaria Bioscience has a consensus price target of $22.50, representing about 577.7% upside from its current price of $3.32.

Amount of Analyst Coverage

Lexaria Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Lexaria Bioscience are expected to decrease in the coming year, from ($4.05) to ($4.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lexaria Bioscience is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lexaria Bioscience is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lexaria Bioscience has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.23% of the float of Lexaria Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Lexaria Bioscience has a short interest ratio ("days to cover") of 3.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lexaria Bioscience has recently increased by 53.37%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexaria Bioscience does not currently pay a dividend.

Dividend Growth

Lexaria Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Lexaria Bioscience this week, compared to 1 article on an average week.

Search Interest

1 people have searched for LEXX on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.39% of the stock of Lexaria Bioscience is held by insiders.

Percentage Held by Institutions

13.06% of the stock of Lexaria Bioscience is held by institutions.

Company Calendar

• Last Earnings: 7/13/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 8/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LEXX
• CIK: 1348362
• Web: www.lexariabioscience.com
• Phone: (250) 765-6424
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lexaria Bioscience: $22.50
• High Price Target: $22.50
• Low Price Target: $22.50
• Potential Upside/Downside: +577.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.90 million
• Net Margins: N/A
• Pretax Margin: -3,987.11%
• Return on Equity: -174.93%
• Return on Assets: -143.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.61
• Quick Ratio: 10.61

Sales & Book Value

• Annual Sales: $710 thousand
• Price / Sales: 9.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.00 per share
• Price / Book: 1.66

Miscellaneous

• Outstanding Shares: 2,110,000
• Free Float: 1,929,000
• Market Cap: $7.01 million
• Optionable: Not Optionable
• Beta: 0.61